Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Evogene Ltd. (EVGN:NASDAQ), powered by AI.
Evogene Ltd. is currently trading at $0.58. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Evogene Ltd. on Alpha Lenz.
Evogene Ltd.'s P/E ratio is -0.5.
“Evogene Ltd. trades at a P/E of -0.5 (undervalued) with strong ROE of 1107.0%. 3Y revenue CAGR of 32.0% highlights clear growth momentum.”
Ask for details →Evogene Ltd. is a biotechnology company that focuses on developing innovative solutions across various life science-based industries, including agriculture, pharmaceuticals, and industrial applications. By leveraging its unique computational predictive biology platform, Evogene aims to evolve new products through enhanced efficiency and precision. The platform integrates extensive databases, advanced algorithms, and big data analytics to identify and optimize traits that increase yield, resistance, and sustainability in crops or address critical health and industrial challenges. As a key player in sectors such as agrochemicals, seed development, and biotechnology, Evogene has established collaborations with leading companies to commercially scale its proprietary discoveries. The company is headquartered in Rehovot, Israel, contributing significantly to advancements in biotechnology that enhance productivity and sustainability, reflecting its growing importance in the global market for biologically driven solutions.
“Evogene Ltd. trades at a P/E of -0.5 (undervalued) with strong ROE of 1107.0%. 3Y revenue CAGR of 32.0% highlights clear growth momentum.”
Ask for details →Evogene Ltd. (ticker: EVGN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 117 employees. Market cap is $5M.
The current price is $0.584 with a P/E ratio of -0.54x and P/B of -56.07x.
ROE is 1106.98% and operating margin is -364.24%. Annual revenue is $4M.